FOLFIRI plus cetuximab—preferred first-line treatment for mCRC

被引：0
|
作者：
Lisa Hutchinson
机构：
来源：
Nature Reviews Clinical Oncology | 2014年 / 11卷 / 10期
关键词：
D O I：
10.1038/nrclinonc.2014.141
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：560 / 560
相关论文
共 50 条
  • [21] Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients
    Tsai, Hsiang-Lin
    Lin, Chih-Hung
    Huang, Ching-Wen
    Yang, I-Ping
    Yeh, Yung-Sung
    Hsu, Wen-Hung
    Wu, Jeng-Yih
    Kuo, Chao-Hung
    Tseng, Fan-Ying
    Wang, Jaw-Yuan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (02): : 1900 - 1910
  • [22] Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
    Kohne, Claus-Henning
    Hofheinz, Ralf
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Twomey, Brian
    Oliner, Kelly Smith
    Boedigheimer, Michael
    Terwey, Jan-Henrik
    Karthaus, Meinolf
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [23] Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
    Kohne, Claus-Henning
    Hofheinz, Ralf D.
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Twomey, Brian
    Oliner, Kelly Smith
    Boedigheimer, Michael
    Terwey, Jan-Henrik
    Karthaus, Meinolf
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] ESTIMATION OF COSTS OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) WITH FOLFIRI, FOLFOX OR XELOX PLUS BEVACIZUMAB, IN FIVE MEXICAN INSTITUTIONS
    Calderillo, Ruiz G.
    VALUE IN HEALTH, 2011, 14 (07) : A539 - A539
  • [25] A COST-EFFECTIVENESS ANALYSIS (CEA) OF CETUXIMAB plus FOLFIRI COMPARED TO BEVACIZUMAB plus FOLFIRI AS FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC): A US ANALYSIS BASED ON LOCATION OF PRIMARY TUMOR
    Evans, R.
    Aggarwal, H.
    Takundwa, R.
    Chin, S.
    Fenwick, E.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [26] Cetuximab plus Xeliri versus cetuximab plus xelox as first-line treatment of patients with metastatic colorectal cancer (MCRC): A randomised trial of the German Aid CRC study group
    Heinernann, V
    Fischer, Von Weikersthal L.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 13 - 13
  • [27] ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) plus BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
    Torrecillas, L.
    Vargas, J.
    VALUE IN HEALTH, 2008, 11 (06) : A469 - A470
  • [28] Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, folfiri and monotherapy for MCRC: First beatrial
    Rivera, F.
    Van, Cutsem E.
    Kretzschmar, A.
    Berry, S.
    DiBartolomeo, M.
    Michael, M.
    Mazier, M.
    Lutiger, B.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2007, 18 : VII19 - VII19
  • [29] Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for MCRC - First beat
    Rivera, F.
    Cunningham, D.
    Michael, M.
    DiBartolomeo, M.
    Kretzschmar, A.
    Berry, S.
    Mazier, M.
    Lutiger, B.
    Van, Cutsem E.
    ANNALS OF ONCOLOGY, 2006, 17 : 23 - 24
  • [30] Cetuximab A Guide to Its Use in Combination with FOLFIRI in the First-Line Treatment of Metastatic Colorectal Cancer in the USA
    Lyseng-Williamson, Katherine A.
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (05) : 317 - 322
12345